Literature DB >> 20237321

Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo.

Sergey Krysov1, Kathleen N Potter, C Ian Mockridge, Vania Coelho, Isla Wheatley, Graham Packham, Freda K Stevenson.   

Abstract

Surface IgM (sIgM) has a key influence on the clinical behavior of chronic lymphocytic leukemia (CLL). We now report that it exists in 2 forms with different N-glycosylation patterns in the mu-constant region. One glycoform is similar to normal B cells in bearing mature complex glycans common to most cell-surface glycoproteins. The other is an immature mannosylated form more characteristic of mu chains in the endoplasmic reticulum. Unmutated CLL (U-CLL) expresses a higher proportion of mannosylated surface mu chains than mutated CLL. Normal B cells express only the mature glycoform but can express the immature form after persistent engagement of sIgM, suggesting that glycan modification is a consequence of antigen exposure. CLL cells express variable proportions of the mannosylated form and can revert to the mature form after incubation in vitro. Both glycoforms are able to signal after sIgM engagement in vitro, leading to enhanced tyrosine phosphorylation. These findings support the concept that CLL cells are continuously exposed to antigen in vivo, driving the N-glycosylation pattern of expressed sIgM toward a mannosylated form, especially in U-CLL. Strikingly, this is reminiscent of follicular lymphoma, where mannosylated Ig is expressed constitutively via N-glycosylation sites in the variable region, suggesting a functional asset for this glycoform.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237321     DOI: 10.1182/blood-2009-12-254847

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 3.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

Review 4.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

5.  Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.

Authors:  Vania Coelho; Sergey Krysov; Amir M Ghaemmaghami; Mohamed Emara; Kathleen N Potter; Peter Johnson; Graham Packham; Luisa Martinez-Pomares; Freda K Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

6.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

7.  SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.

Authors:  Nili Dezorella; Ben-Zion Katz; Mika Shapiro; Aaron Polliack; Chava Perry; Yair Herishanu
Journal:  Haematologica       Date:  2016-07-21       Impact factor: 9.941

Review 8.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 9.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

10.  Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients.

Authors:  L Renee Ruhaak; Kyoungmi Kim; Carol Stroble; Sandra L Taylor; Qiuting Hong; Suzanne Miyamoto; Carlito B Lebrilla; Gary Leiserowitz
Journal:  J Proteome Res       Date:  2016-02-24       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.